Loading...

IMRX IMMUNEERING CORP Expansion Plans 8-K Filing

MMNR

MRX

IMMUNEERING CORP

(IMRX)

2026 8-K

Financial Results Report

Clinical Trial Update

Financial Results Announced

Stock Offering Details

Securities Purchase Agreement

Private Placement Raised

Quarterly Results Update

Clinical Trials

Financial Statements

Financial Results

Clinical Trial Update

Clinical Trial Update

Financial Results

Director Appointment

Clinical Trial Update

Financial Results Announcement

Annual Meeting of Stockholders

Repricing of Options

Appointment of Director

Financial Results Announcement

Amendments to Bylaws

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Public Offering

Results of Operations and F...

Financial Results Announcement

External Links:

On January 7, 2026, Immuneering Corp announced positive interim results from its clinical trial of atebimetinib, showing a 64% overall survival at 12 months in pancreatic cancer patients, compared to 35% for standard care.

AI Assistant

IMMUNEERING CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.